Immunogenicity and Reactogenicity of 2009 Influenza A (H1N1) Inactivated Monovalent Non-Adjuvanted Vaccine in Elderly and Immunocompromised Patients

Imagem de Miniatura
Arquivos
art_MIRAGLIA_Immunogenicity_and_Reactogenicity_of_2009_Influenza_A_H1N1_2011.PDF (163.61 KB)
Citações na Scopus
37
Tipo de produção
article
Data de publicação
2011
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
PUBLIC LIBRARY SCIENCE
Autores
MIRAGLIA, Joao L.
VISO, Ana T. R.
TAYRA, Angela
Citação
PLOS ONE, v.6, n.11, article ID e27214, 7p, 2011
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Immunosuppressed individuals present serious morbidity and mortality from influenza, therefore it is important to understand the safety and immunogenicity of influenza vaccination among them. Methods: This multicenter cohort study evaluated the immunogenicity and reactogenicity of an inactivated, monovalent, non-adjuvanted pandemic (H1N1) 2009 vaccine among the elderly, HIV-infected, rheumatoid arthritis (RA), cancer, kidney transplant, and juvenile idiopathic arthritis (JIA) patients. Participants were included during routine clinical visits, and vaccinated according to conventional influenza vaccination schedules. Antibody response was measured by the hemagglutination-inhibition assay, before and 21 days after vaccination. Results: 319 patients with cancer, 260 with RA, 256 HIV-infected, 149 elderly individuals, 85 kidney transplant recipients, and 83 with JIA were included. The proportions of seroprotection, seroconversion, and the geometric mean titer ratios postvaccination were, respectively: 37.6%, 31.8%, and 3.2 among kidney transplant recipients, 61.5%, 53.1%, and 7.5 among RA patients, 63.1%, 55.7%, and 5.7 among the elderly, 59.0%, 54.7%, and 5.9 among HIV-infected patients, 52.4%, 49.2%, and 5.3 among cancer patients, 85.5%, 78.3%, and 16.5 among JIA patients. The vaccine was well tolerated, with no reported severe adverse events. Conclusions: The vaccine was safe among all groups, with an acceptable immunogenicity among the elderly and JIA patients, however new vaccination strategies should be explored to improve the immune response of immunocompromised adult patients.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/22876
Referências
  1. Tebas P, 2010, AIDS, V24, P2187, DOI 10.1097/QAD.0b013e32833c6d5c
  2. Liang XF, 2010, LANCET, V375, P56, DOI 10.1016/S0140-6736(09)62003-1
  3. Zhu FC, 2009, NEW ENGL J MED, V361, P2414, DOI 10.1056/NEJMoa0908535
  4. Crum-Cianflone NF, 2011, CLIN INFECT DIS, V52, P138, DOI 10.1093/cid/ciq019
  5. Petty RE, 2004, J RHEUMATOL, V31, P390
  6. Heinze G, 2002, STAT MED, V21, P2409, DOI 10.1002/sim.1047
  7. WHITE H, 1980, ECONOMETRICA, V48, P817, DOI 10.2307/1912934
  8. Miller E, 2010, LANCET, V375, P1100, DOI 10.1016/S0140-6736(09)62126-7
  9. Saad CGS, 2011, ANN RHEUM DIS, V70, P1068, DOI 10.1136/ard.2011.150250
  10. Plennevaux E, 2010, LANCET, V375, P41, DOI 10.1016/S0140-6736(09)62026-2
  11. Ogimi C, 2011, PEDIATR INFECT DIS J, V30, P208, DOI 10.1097/INF.0b013e3181f7ce44
  12. McElhaney JE, 2011, AGEING RES REV, V10, P379, DOI 10.1016/j.arr.2010.10.008
  13. [Anonymous], 2009, GLOB AL RESP WHO REC
  14. Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002
  15. Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333
  16. Kunisaki KM, 2009, LANCET INFECT DIS, V9, P493, DOI 10.1016/S1473-3099(09)70175-6
  17. Weng HY, 2009, AM J EPIDEMIOL, V169, P1182, DOI 10.1093/aje/kwp035
  18. ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302
  19. Baguelin M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017074
  20. Centers for Disease Control and Prevention (CDC), 2009, MMWR-MORBID MORTAL W, V58, P467
  21. *EMA, 1996, EUR MED AG PUBL
  22. EMA. Committee for Proprietary Medicinal Products (CPMP), 2004, CPMPVEG471703 EMA EU
  23. HOBSON D, 1972, J HYG-CAMBRIDGE, V70, P767
  24. Huber PJ, 1967, P 5 BERK S MATH STAT, P221, DOI 10.3238/ARZTEBL.2011.0523A
  25. ICH, 1996, INT C HARM TECHN REQ
  26. Kanakoudi-Tsakalidou F, 2001, CLIN EXP RHEUMATOL, V19, P589
  27. Kendal AP, 1982, CONCEPTS PROCEDURES, pB17
  28. MALLESON PN, 1993, J RHEUMATOL, V20, P1769
  29. *MS, 2010, BAL PARC VAC GRIP A
  30. *MS SVS DVE PNI, 2010, ESTR NAC VAC VIR INF
  31. Plennevaux E, 2011, VACCINE, V29, P1569, DOI 10.1016/j.vaccine.2010.12.116
  32. USFDA. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research, 2007, GUID IND CLIN DAT NE
  33. WHO, 2005, WKLY EPIDEMIOL REC, V80, P277
  34. WHO, 2009, WKLY EPIDEMIOL REC, V84, P249
  35. Yanagisawa N, 2011, VACCINE, V29, P5694, DOI 10.1016/j.vaccine.2011.06.003

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/ICr
Artigos e Materiais de Revistas Científicas - IMT
Artigos e Materiais de Revistas Científicas - LIM/24
Carregar mais